



*EMA Workshop on the therapeutic use of
bacteriophages*

London, June 8th 2015

Laurent Bretaudeau, R&D Director

A decorative pink brushstroke is located at the bottom of the slide.



Presentation outlines

- Foreword : Company overview / phage therapy field,
- Strategy for the management of bacteria banks, phage banks, drug substances, drug products,
- Quality control scheme,
- Practical point of view from a CMO: experience-based considerations.



Clean Cells' overview



Founded in 2000

Located near Nantes, France

Team = 50 persons

GLP and GMP certified

Objective: To become a key player in biopharmaceutical development for human medicine and animal health



Business 1: Quality controls of Biopharmaceuticals,




Business 2: Manufacturing of biological products for clinical trials.



Clean Cells & Phage therapy

Participation in the Phagoburn's consortium



The research leading to these results has received funding from the European Community's Seventh Framework Programme FP7 (2007-2013) under grant agreement n°601857





Phage production framework

Phage products are considered as:

- Anti-infectious products,
- Biological products,
- Sterile products.



Practical organisation:

- Management of production bacteria as cell banks : R&D, Master and Working,
- Management of phages as stocks : R&D, Master and Working,
- Drug Substance Process and Drug Product Process with several steps, under GMP organization.



Phage production strategy

Host bacteria

Phage A

Documentation

Research Cell Bank

Isolate

Characterization datasheet

Master Cell Bank

Research Phage Stock

Characterization datasheet

Working Cell Bank

Master Phage Stock

Manufacturing batch file

Working Phage Stock

Supporting data

Production process

Drug substance / Phage A


Cocktail preparation

Fill & finish

Drug product / Phages A, B, C ...

GMP grade

Batch certification





Phage GMP production

Parameter	Pre-requisites
Biological starting material	Full characterization available
Raw material (e.g. medium)	Selected and controlled
Single-use consumables	Selected and controlled
Classification of the production area	Class A in class C for the banks, Isolator (class A) for drug substances & products Constant environmental monitoring
Human resources	Trained staff
Equipments	Qualified
Quality controls	Validated methods (except for supporting data)
Production	Validated method + Media Process Test / Media Fill Test + Pilot runs



GOAL = Manufacturing under control



Quality control scheme

- Objective of QC: ensure the quality of the biological material and of the process at different steps

Bacteria: strategy inspired from European Pharmacopoeia 5.14

QC	Methods	RCB	MCB	EOPC
Viability	Titration	+	+	-
Identity	Full genome sequence	+	-	-
	Strain Characterization -16s DNA sequencing	+	+	-
	Genotyping – RAPD-PCR based method	+	+	+ *
Purity	Plating	+	+	-
	Absence of bacteriophages	+	+	-

* In case of production failure

Additional criteria = fit for production of the phage(s)



Quality control scheme

Phages: strategy inspired from viral vaccine strains characterization

QC	Methods	Research Phage Stock (RPS)	Master Phage Stocks (MPS)	Drug substance	Drug product = cocktail
Viability	Titration	+	+	+	+
Identity	Host range	+	+	-	-
	Full genome sequence	+	-	-	-
	DNA restriction profile	+	-	-	-
	Genotyping – RAPD-PCR based method	+	+	+	-
	Protein profile	-	-	+	-
	Morphotype by e.m.	+	-	-	-
Purity	Sterility	+	+	+	+
	Endotoxins	-	-	+	+
	Host Cell DNA	-	-	+	+
	Total proteins	-	-	+	+
	Visual aspect	-	-	+	+
Other	pH	-	-	+	+
	Volume	-	-	-	+
	Integrity of container	-	-	-	+



Experience-based considerations

- Amplification: Short duration ~17h, reduced risk of genetic instability
Scale-up appears feasible
- Purification: Tangential Flow Filtration +/- chromatographic purification
= f (simplicity, yield, impurities)
TFF : robust platform process
- Sterile filtration: Feasible without impacting phage titer
Significant advantage for multiple indications
- Fill & Finish: Aseptic step (under isolator)
Glass vials, alternative contents possible
- Stability: > 12 months, in saline buffer
Storage +5°C
Rather stable and easy-to-store product



Acknowledgments

Clean Cells

Isabelle ARNAUD (QP)

Audrey LARRIEU (GMP Op.)

Alicia GUICHETEAU (Prod.)

François PEDELABORDE (QC dev.)

Karine TREMBLAIS (QC dev.)

Soizic REMAUD (QC dev.)

Emeline MATHE (QC)

Anne JAFFRE (QC)

Théophile HERSANT (QC)

Annaïck BARBOU (QC)

Virginie LE CAM (QC)

Valérie BERNARD (QA)

Pherecydes Pharma

Jérôme GABARD

Patrick CHAMPION-ARNAUD

Hélène BLOIS

Hôpital d'Instruction des Armées - Percy

Patrick JAULT

Thomas LECLERC

Queen Astrid Military Hospital

Gilbert VERBEKEN

Daniel DE VOS

Jean-Paul PIRNAY

Univ. Lausanne - CHUV

Grégory RESCH

Yok-Ai QUE

Other partners and contributors to Phagoburn's project

In RED, presenting or attending contributors



The research leading to these results has received funding from the European Community's Seventh Framework Programme FP7 (2007-2013) under grant agreement n°601857





CLEAN CELLS

Rue Marie Curie – Parc Eco 1 - 85600 Boufféré – France

TEL : +33 (0)2 51 09 27 57 / FAX : +33 (0)2 51 09 27 58

contact@clean-cells.com

For more information :

www.clean-cells.com